According to Marinova, Maritech fucoidan significantly inhibited the production of pro-inflammatory biomarkers relevant to acute and chronic gut conditions in unpublished study.
Marinova (Tasmania, Australia) has announced the results of research recently conducted on Maritech fucoidan, a branded bioactive compound extracted from Undaria pinnatifida and Fucus vesiculosus microalgae. According to a press release from the company, Maritech fucoidan significantly inhibited the production of pro-inflammatory biomarkers relevant to acute and chronic gut conditions. Compared to controls, tests of ex vivo human blood demonstrated inhibition of TNF-α, IL-1β, and IL-6 by 70%, 54%, and 43%, respectively. The study has not been published.
Prolonged and raised levels of TNF-α and IL-1β are linked to inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis. IL-6 also plays a central role in uncontrolled intestinal inflammation, altering the balance between pro-inflammatory and immunosuppressive immune cells. Raised levels of IL-6 has been associated with IBD as well as colon cancer.
“It’s truly exciting that a naturally derived marine ingredient has demonstrated such profound anti-inflammatory benefits with great potential to improve gut and digestive health,” said Helen Fitton, PhD, chief scientist for Marinova, in a press release. “Fucoidan has long been valued for its ability to address both local and systemic inflammation. This activity is ascribed to its biological role in protecting the seaweed plant from inflammation caused by UV light and pathogens.”
The company says it is set to commence a human clinical trial featuring Maritech fucoidan that targets the gut microbiome.